Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

RCUSArcus Biosciences, Inc.Finished

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant · Androgen-Resistant Prostatic Neoplasms · Castration Resistant Prostatic Neoplasms · Prostatic Cancer, Castration-Resistant

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Aug 2024, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 1/2
Patients
173 (final count)
Started
Jul 7, 2020
Main results expected
Aug 30, 2024
Fully finished
Aug 30, 2024
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Objective Response Rate (ORR) in Stage 1 and 2

    Measured over: From study enrolment until participant discontinuation, or first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 3-5 years)

  • Incidence and Severity of AEs and Serious Adverse Events (SAEs) in Stage 1

    Measured over: From first dose date to 90 days after the last dose (approximately 1.5 years)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2024-08-30, no fading

Raw record changes

  • none yet

Trial ID NCT04381832 · record last updated 2025-07-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04381832) ↗